Sequences from 82 protease inhibitors (PI)-experienced patients were analysed for the presence of previously described in-vitro resistance mutations to PA-457 located in the C-terminal capside (H226Y, L231F, L231M) and in the N-terminal SP1 (A1V, A3T, A3V) within the CA-SP1 boundary domain. Overall, the CA-SP1 cleavage site was highly conserved in PI pre-treated patients and only one patient showed an L231M mutation. The impact of this mutation should be further addressed in vivo.
aLaboratoire de Virologie, Université Pierre et Marie Curie (Paris 6), France
bService de Médecine Interne, France
cService des Maladies Infectieuses, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France
dINSERM U720, Université Pierre et Marie Curie (Paris 6), Paris, France.
Received 7 December, 2006
Accepted 15 December, 2006